MSD's confidence in its anti-TL1A antibody tulisokibart in inflammatory diseases has been made apparent by a decision to start trials of the drug in three more indications. Already in phase 3 testing ...

MSD's cancer immunotherapy Keytruda will soon be available as a subcutaneous injection that does away with the need to visit an infusion clinic. Keytruda Qlex (pembrolizumab and berahyaluronidase alfa ...

So, you like games? Vulture’s Movies Fantasy League just kicked off its new season. It’s fun, it’s free, and there are some killer prizes on the line. Sign up to play here, or learn more at the MFL ...